BACKGROUND Low cardiac output syndrome (LCOS) after congenital cardiac surgery has
an incidence of up to 25%. Preventing and treating LCOS is of pivotal importance as LCOS …

Introduction Low cardiac output syndrome (LCOS) is a significant cause of morbidity and the
leading cause of mortality after pediatric cardiac surgery. Levosimendan has been shown …

Levosimendan increasingly has been used to treat heart failure and cardiac dysfunction in
pediatric patients. Currently, there is only limited evidence that this drug positively affects …

Background: Prophylactic milrinone is commonly used to prevent Low Cardiac Output
Syndrome (LCOS) after pediatric cardiac surgery. This study compares the use of …

Background Low cardiac output syndrome remains a serious complication, and accounts for
substantial morbidity and mortality in the postoperative course of paediatric patients …

Background: Levosimendan, a calcium sensitizer, enhances the myocardial function by
generating more energy-efficient myocardial contractility than that achieved through …

Purpose To evaluate the safety and efficacy of levosimendan in neonates with congenital
heart disease undergoing cardiac surgery with cardiopulmonary bypass (CPB). Methods …

Low-Cardiac-Output Syndrome (LCOS) early after cardiopulmonary bypass (CPB) is a well-
known problem in the postoperative course after complex congenital heart surgery, which …

Low cardiac output is one of the most common complications after cardiac surgery.
Levosimendan, a new inotrope agent, has been demonstrated in adult patient to be an …

[Retrospective descriptive study about the use of levosimendan in children undergoing surgical
correction for congenital heart disease]. - Abstract - Europe PMC Sign in | Create an account …